Eric D. Donnenfeld, MD; underscores the significance of an FDA approved treatment for Demodex blepharitis as well as past alternative treatments. This is a video synopsis/summary of an Insights ...

Please provide your email address to receive an email when new articles are posted on . Demodex blepharitis is so common that it makes up more than two thirds of all blepharitis cases. In fact, nearly ...

An overview of the current landscape of available treatment options for Demodex blepharitis is analyzed. This is a video synopsis/summary of a discussion involving Elizabeth Yeu, MD. Yeu discusses how ...

Credit: Tarsus Pharmaceuticals. Xdemvy is supplied as an ophthalmic solution containing lotilaner 0.25% (2.5mg/mL) in a 10mL bottle; it is expected to be available by the end of August 2023. The Food ...

XDEMVY is the first and only approved therapeutic for Demodex blepharitis, a highly prevalent eyelid disease that impacts approximately 25 million eye care patients in the U.S. XDEMVY targets the root ...

Please provide your email address to receive an email when new articles are posted on . A variety of skin diseases can be caused by an imbalance in the immune mechanism, triggered by a high Demodex ...

Deal expands access to TP-03 for approximately 40 million patients with Demodex blepharitis and 70 million patients with Meibomian Gland Disease in China, the world’s second largest healthcare market ...

IRVINE, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize ...

The Demodex mite is a ubiquitous microscopic ectoparasite that colonises the pilosebaceous units on human skin, notably the eyelids, where it may contribute to conditions such as blepharitis and ...